Chemosensitization of solid tumor cells by alteration of their susceptibility to apoptosis

Current Opinion in Investigational Drugs

Volumn 3, Issue 4, 2002, Pages 641-647

  Cree, Ian A ^a   Knight, Louise ^a   Di Nicolantonio, Federica ^a   Sharma, Sanjay ^a   Gulliford, Tim ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Chemosensitization; Chemotherapy; Resistance; Synergy

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ERLOTONIB; GEFITINIB; GROWTH FACTOR RECEPTOR; IMATINIB; IRINOTECAN; ISIS 3521; JANUS KINASE; MIDOSTAURIN; ONYX 015; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM DERIVATIVE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE C INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; STAT PROTEIN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; DRUG TARGETING; DRUG UPTAKE; ENZYME INHIBITION; GENE MUTATION; GENE THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; NONHUMAN; ONCOGENE NEU; REVIEW; SIDE EFFECT; SOLID TUMOR; CELL TRANSFORMATION; DRUG ANTAGONISM; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; DRUG SYNERGISM; GENE THERAPY; HUMAN; NEOPLASMS; RECEPTORS, GROWTH FACTOR; SUPPORT, NON-U.S. GOV'T; HUMANS;

EID: 0036528398     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Cell death: The significance of apoptosis
2. Apoptosis and carcinogenesis
3. The hallmarks of cancer
4. Induction of apoptosis in fibroblasts by c-myc protein
5. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines
6. Bcl-2: An antidote to programmed cell death
7. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
8. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisence Bcl-2 oligodeoxynucleotides
9. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model
10. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides
11. Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated p53 gene transfer in human bladder cancer model
12. HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: An isolated instance or a trend?
13. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction
14. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors
15. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
16. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth
17. COX2 inhibitors in cancer treatment and prevention: A recent development
18. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
19. Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents
20. Epidermal growth factor receptor family and chemosensitization
21. The epidermal growth factor receptor and its inhibition in cancer therapy
22. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
23. Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033
24. Rapamycin's resurrection: A new way to target the cancer cell cycle
25. Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo
26. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
27. +/- mice
28. Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN
29. STAT proteins: Novel molecular targets for cancer drug discovery
30. STAT signaling in head and neck cancer
31. Farnesyltransferase inhibitors
32. A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
33. Antisense therapeutics: Lessons from early clinical trials
34. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)
35. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
36. U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways
37. Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells
38. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells
39. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
40. Current status of clinical trials of farnesyltransferase inhibitors
41. STI571: A paradigm of new agents for cancer therapeutics
42. STI571 (imatinib mesylate): A tale of a targeted therapy
43. Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options
44. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications
45. Proteasome inhibition in cancer: Development of PS-341
46. Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells
47. Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells
48. Antisense against protein kinase C-α mRNA makes sense for cancer therapy?
49. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function
50. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-α, in patients with advanced cancer
51. Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP 64128A) in patients with cancer
52. Antitumor activity of protein kinase C inhibitors and cisplatin in human head and neck squamous cell carcinoma lines
53. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics
54. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro
55. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
56. Death and methylation
57. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo
58. Chemosensitization of pancreatic cancer by inhibition of the 26s proteasome
59. HSP90 as a new therapeutic target for cancer therapy: The story unfolds
60. Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter
61. Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy
62. Replication-selective oncolytic adenoviruses: Virotherapy aimed at genetic targets in cancer
63. Simultaneous genetic chemoprotection of normal marrow cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model
64. Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chlorethyl)-1-nitrosourea and cisplatin
65. Efficient induction of apoptosis by ONYX-O15 adenovirus in human colon cancer cell lines regardless of p53 status
66. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
67. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity
68. Drug resistance in ovarian cancer - The role of p53
69. Evaluating HER2 amplification and overexpressing in breast cancer
70. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation
71. Individualizing chemotherapy for solid tumors - Is there any alternative?